Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.65 |
| ▸ | KDM5A | P29375 | 2/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384406 | 0.88 | XDH (0.53) | XDHKDM5AKDM5CKMOKDM5B | |
| SCHEMBL13722439 | 0.83 | XDH (0.56) | XDHKDM5CKMO | |
| SCHEMBL13722581 | 0.82 | XDH (0.59) | XDHKDM5AKDM5CKMOKDM5B | |
| SCHEMBL14384168 | 0.78 | XDH (0.52) | XDHKDM5CKMO | |
| SCHEMBL3586842 | 0.75 | KDM4E (0.40) | XDH | |
| SCHEMBL4345222 | 0.71 | XDH (0.40) | XDHALDH1A1 | |
| SCHEMBL13123372 | 0.71 | XDH (0.36) | XDH | |
| SCHEMBL1329694 | 0.70 | XDH (0.54) | XDHKDM5CKMO | |
| SCHEMBL14384227 | 0.70 | XDH (0.54) | XDHKMO | |
| SCHEMBL1331290 | 0.70 | XDH (0.52) | XDHKDM5CKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | claimed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | claimed |
| US-7820700-B2 | 2-phenylpyridine derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | XDH 2/4885KDM5A 969/4885KDM5C 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.